A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
Status:
Completed
Trial end date:
2018-04-02
Target enrollment:
Participant gender:
Summary
This is a multi-center open-label dose-escalation study of a novel compound (MDV3100) to
treat patients with castration-resistant (hormone-refractory) prostate cancer. Additional
patients will be enrolled in expanded cohorts at doses determined to be tolerable. Patients
who tolerate the drug and do not progress will be allowed to continue to look for PSA
response.
Phase:
Phase 1
Details
Lead Sponsor:
Medivation, Inc. Pfizer
Collaborators:
Astellas Pharma Inc Medivation LLC, a wholly owned subsidiary of Pfizer Inc.